10/11/2025
🔬 Fudan Zhongshan Hospital has published a groundbreaking Nature Cancer study demonstrating that combining cryoablation using Hygea's Co-Ablation system with immunotherapy achieves remarkable clinical outcomes in patients with advanced intrahepatic cholangiocarcinoma.
In the CASTLE-01 phase II trial, conducted with Hygea's Co-Ablation system, the treatment achieved an objective response rate of 75%, a disease control rate of 100%, and a median overall survival of 25.4 months.
Read the paper: https://www.nature.com/articles/s43018-025-01058-2
This landmark study underscores how cryoablation can enhance tumor immunogenicity and amplify systemic antitumor immunity — marking a new milestone in immuno-cryoablation cancer therapy.
Wang and colleagues report the clinical results and immunological correlates of a phase 2 clinical trial of cryoablation plus lenvatinib and sintilimab in persons with advanced or metastatic intrahepatic cholangiocarcinoma.